Estimulación Magnética Trascraneal "Theta-Burst Intermitente" en un paciente con Trastorno del Espectro Autista: Reporte de un caso / Intermittent Theta-Burst Transcranial Magnetic Stimulation in a Patient with Autism Spectrum Disorder: A Case Report

Resumen Introducción: La estimulación magnética transcraneal (EMT) es una opción potencial de tratamiento para la sintomatología de trastorno del espectro autista. Objetivos: Determinar la eficacia de la EMT en modalidad theta-burst intermitente (ETBi) sobre la corteza pre frontal dorso lateral izquierda (CDLPF) en el manejo de comportamientos patológicos asociados con TEA. Pacientes y Métodos: Paciente masculino de 10 años de edad diagnosticado con TEA con (ADOS) Autistic Diagnostic Observation Schedule, presenta una historia familiar de una hermana menor con TEA. Tanto el estudio de Resonancia Magnética encéfalo (IRM) y IRM funcional (IRMf) con paradigma emocionales se efectuaron antes del tratamiento de ETBi, inmediatamente después de tratamiento ETBi, y después de 6 meses de tratamiento con ETBi. Resultados: La prueba de ATEC reporto mejoría en las escalas de comunicación, cognición, social y comportamiento, 83%,81%,72% y 52% respectivamente. La puntuación total mejoro un 66% inmediatamente después de tratamiento y 55% en un periodo de 6 meses. La IRMf revelo la activación de la corteza frontal, parietal y occipital antes del tratamiento con ETBi y persistiendo la mejoría por 6 meses. Conclusión: ETBi una técnica de neuromodulación no invasiva bien tolerado que requiere un tiempo de administración menor que el tratamiento estándar.

Abstract Background: Transcranial magnetic stimulation (TMS) is a potential treatment option for autism spectrum disorder (ASD) symptomatology. Objectives: To determine the efficacy of the TMS intermittent theta-burst stimulation (iTBS) protocol over the left dorsolateral prefrontal cortex (DLPFC) in the management of pathological behaviors associated with ASD. Patient/Methods: A 10-year-old male diagnosed with ASD by the Autism Diagnostic Observation Schedule (ADOS) presented with a family history of ASD with a younger sister diagnosed with the same disorder. Both magnetic resonance imaging (MRI) and functional MRI (fMRI) scans for emotional paradigms were performed before the iTBS treatment, immediately after the iTBS treatment, and after 6 months of iTBS treatment. Results: The ATEC reports revealed improvement in communication, cognition, sociability, and behavior scales by 83%, 81%, 72%, and 52%, respectively. The overall score improved by 66% immediately after the treatment and by 55% lasting over a 6-month period. The fMRI revealed the activation of the frontal, parietal, and occipital cortex before iTBS treatment, and a better integration and activation of the frontal, temporal, and occipital cortex after iTBS treatment and persisted after 6 months. Conclusions: iTBS is a well-tolerated, non-invasive neuromodulation technique that requires relatively less administration than the standard treatment.

Glucose-6-Phosphate dehydrogenase deficiency incidence in a Hispanic population.

Glucose-6-phosphate dehydrogenase deficiency (D-G6PD) is a common erythroenzymopathy that needs to be addressed as an important public health issue. Proper population monitoring is needed to anticipate clinical complications. A joint venture between Genomi-k (a Mexican company focused on newborn screening) and several university researchers conducted a retrospetive study for D-G6PD based on 156,152 newborn screening reports belonging to the Mexican population comprising a period of 10 years. We identified 540 male newborns affected with this deficiency, representing an incidence of 6.78 cases per 1,000 newborn males. A single double mutation of G202A:A376G was detected in 97.22% of cases. In regions where there is an absence of a national centralized health data for D-G6PD, information from a non-probabilistic large population sample can be used as a national incidence subrogate.

Mutación en el gen supresor tumoral PTCH1 en el síndrome de Gorlin. Presentación de un caso / Mutation in the PTCH1 tumor suppressor gene in Gorlin Syndrome. A case report

El síndrome de Gorlin, también conocido como síndrome del carcinoma basocelular nevoide (SCBN), es una enfermedad hereditaria, autosómica dominante, con penetrancia alta y expresividad clínica variable. El SCBN se caracteriza por la presencia de múltiples carcinomas basocelulares, fibromas de ovario y una variedad de características clínicas, clasificadas según criterios mayores y menores que permiten orientar el diagnóstico. El SCBN corresponde a una enfermedad genética con baja incidencia y poca prevalencia en México. Está asociado a mutaciones en el gen supresor de tumores PTCH1. Presentamos el caso de una niña de 13 años, producto del primer embarazo de padres sanos y sin antecedentes heredofamiliares de importancia. Los signos clínicos en esta paciente incluían los siguientes: macrocefalia, frontal amplio, puente nasal ancho, telecanto y paladar alto y ojival. En la piel se observaron 8 nevos y hoyuelos palmares o plantares. Mediante un estudio radiológico se observó la presencia de quistes odontogénicos, que eran recurrentes. El estudio molecular demostró una mutación heterocigota en el gen supresor de tumores PTCH1. Los hallazgos mostraron una mutación novel, no descrita en la bibliografía o en bases de datos públicas; sin embargo, la mutación expresa las manifestaciones fenotípicas características del SCBN. Actualmente, no existe un tratamiento definitivo para esta afección, por lo que es necesario un abordaje preventivo multidisciplinario y el asesoramiento genético (AU)

Gorlin syndrome is a hereditary disease, and it is also known as nevoid basal cell carcinoma (NBCC). NBCC follows an autosomal dominant inheritance pattern, with high penetrance and variable clinical expression. NBCC is characterized by multiple basal cell carcinomas, ovarian fibroma and a variety of clinical manifestation known as minor or mayor criteria. NBCC is a genetic disease with low incidence in México and it is associated with mutated PTCH1 suppressor gen. We present the case of a 13 years old feminine patient was a healthy product of the first gestation of parents with no history of disease. Her clinical characteristics include macrocephaly, broad forehead, broad nasal bridge, telecanthus, high-arched palate, with 8 palmar and plantar pits. The radiology dental studies showed chists odontogenic with a recurrent pattern. Molecular studies showed a heterocigotic mutation in the suppressor gene PTCH1. Molecular analysis showed a novel mutation and clinical manifestation of the NBCC, not described before. For the NBCC there is no definitive treatment, and a multidisciplinary medical team is necessary for prevention and genetic counseling (AU)

Cultura de seguridad del paciente en estudiantes de pregrado en ciencias de la salud / Safety culture in pre-graduate health sciences students

No disponible

Score clínico para el descarte de neumonía por Mycoplasma pneumoniae / Clinical score to rule out pneumonia due to Mycoplasma pneumoniae

INTRODUCCIÓN: La prueba de oro para el diagnóstico de la neumonía secundaria a Mycoplama pneumoniae es la detección de IgM en pruebas seriadas, ya que una prueba aislada para IgM tiene una sensibilidad del 31,8%. Al existir un cuadro clínico diferenciable de la neumonía por M. pneumoniae de otras etiologías es posible realizar un score clínico para su diagnóstico temprano. OBJETIVO: Elaboración de un score clínico para el descarte de neumonía secundaria a M. pneumoniae. METODOLOGÍA: Se evaluaron 302 expedientes; población de 0 a 18 años con diagnóstico de neumonía. Se obtuvieron 2 grupos: Mycoplasma positivo y Mycoplasma negativo, y utilizando distintas variables en la historia clínica se elaboró un score clínico. RESULTADOS: Treinta y cuatro casos se clasificaron en Mycoplasma positivo y 268 en Mycoplasma negativo. Las variables relevantes para la elaboración del score fueron edad, días con tos y días con fiebre, con lo que se conformó el score tos, edad, fiebre (TEF). Se asignaron rangos para cada variable y puntos para cada rango. Un valor de igual o mayor a 5 equivale a un score positivo. Se aplicó el score TEF a los 302 casos resultando ahora en 164 casos Mycoplasma positivo y 138 Mycoplasma negativo. Este score resultó en una sensibilidad del 85% y especificidad del 49%. CONCLUSIÓN: El score TEF tuvo mejor sensibilidad que otras herramientas diagnósticas clínicas. Con un valor predictivo negativo del 96% es posible descartar anticipadamente una neumonía por M. pneumoniae. Se requiere realizar un estudio prospectivo para verificar la utilidad de nuestro score

INTRODUCTION: The gold standard for the diagnosis of pneumonia secondary to Mycoplasma pneumoniae is the serial measurement of IgM, since an isolated test for IgM has a poor sensitivity of 31.8%. A pneumonia due to Mycoplasma pneumoniae could be of clinically different origins, thus it is possible to perform a clinical score for its early diagnosis. OBJECTIVE: To develop a clinical score in order to rule out a pneumoniae secondary to Mycoplasma pneumoniae. METHODOLOGY: A total of 302 patients from 0 to 18 years-old, with a diagnosis of pneumonia were evaluated and divided into two groups: Mycoplasma positive and Mycoplasma negative. Using different variables in the medical records a clinical score was calculated. RESULTS: Of the 302 cases studied, 34 were classified as Mycoplasma positive and 268 as Mycoplasma negative. The variables relevant to the calculation of the score were age, days with fever, and days with cough, thus providing the CAF (Cough, Age, Fever) score. Ranges were assigned for each variable and points were given for each range. A value greater than or equal to 5 meant a positive score. The CAF score was applied to the 302 cases, resulting in 164 cases of Mycoplasma positive and 138 cases of Mycoplasma negative. The CAF score had a sensitivity of 85% and specificity of 49%. CONCLUSION: The CAF score had better sensitivity than other clinical diagnostic tools. With a negative predictive value of 96% it is possible to rule out a pneumonia secondary to M. pneumoniae. The study requires a prospective study to verify the usefulness of our score

[Clinical score to rule out pneumonia due to Mycoplasma pneumoniae]. / Score clínico para el descarte de neumonía por Mycoplasma pneumoniae.

INTRODUCTION: The gold standard for the diagnosis of pneumonia secondary to Mycoplasma pneumoniae is the serial measurement of IgM, since an isolated test for IgM has a poor sensitivity of 31.8%. A pneumonia due to Mycoplasma pneumoniae could be of clinically different origins, thus it is possible to perform a clinical score for its early diagnosis. OBJECTIVE: To develop a clinical score in order to rule out a pneumoniae secondary to Mycoplasma pneumoniae. METHODOLOGY: A total of 302 patients from 0 to 18 years-old, with a diagnosis of pneumonia were evaluated and divided into two groups: Mycoplasma positive and Mycoplasma negative. Using different variables in the medical records a clinical score was calculated. RESULTS: Of the 302 cases studied, 34 were classified as Mycoplasma positive and 268 as Mycoplasma negative. The variables relevant to the calculation of the score were age, days with fever, and days with cough, thus providing the CAF (Cough, Age, Fever) score. Ranges were assigned for each variable and points were given for each range. A value greater than or equal to 5 meant a positive score. The CAF score was applied to the 302 cases, resulting in 164 cases of Mycoplasma positive and 138 cases of Mycoplasma negative. The CAF score had a sensitivity of 85% and specificity of 49%. CONCLUSION: The CAF score had better sensitivity than other clinical diagnostic tools. With a negative predictive value of 96% it is possible to rule out a pneumonia secondary to M. pneumoniae. The study requires a prospective study to verify the usefulness of our score.

Intracellular S-adenosylhomocysteine concentrations predict global DNA hypomethylation in tissues of methyl-deficient cystathionine beta-synthase heterozygous mice.

Because S-adenosylmethionine (SAM) and S-adenosylhomocysteine (SAH) are the substrate and product of essential methyltransferase reactions; the ratio of SAM:SAH is frequently used as an indicator of cellular methylation potential. However, it is not clear from the ratio whether substrate insufficiency, product inhibition or both are required to negatively affect cellular methylation capacity. A combined genetic and dietary approach was used to modulate intracellular concentrations of SAM and SAH. Wild-type (WT) or heterozygous cystathionine beta-synthase (CBS +/-) mice consumed a control or methyl-deficient diet for 24 wk. The independent and combined effect of genotype and diet on SAM, SAH and the SAM:SAH ratio were assessed in liver, kidney, brain and testes and were correlated with relative changes in tissue-specific global DNA methylation. The combined results from the different tissues indicated that a decrease in SAM alone was not sufficient to affect DNA methylation in this model, whereas an increase in SAH, either alone or associated with a decrease in SAM, was most consistently associated with DNA hypomethylation. A decrease in SAM:SAH ratio was predictive of reduced methylation capacity only when associated with an increase in SAH; a decrease in the SAM:SAH ratio due to SAM depletion alone was not sufficient to affect DNA methylation in this model. Plasma homocysteine levels were positively correlated with intracellular SAH levels in all tissues except kidney. These results support the possibility that plasma SAH concentrations may provide a sensitive biomarker for cellular methylation status.